New 3D Tumor Models Challenge Conventional Drug Testing Methods
Researchers have developed sophisticated 3D tumor models that more accurately mimic pancreatic cancer’s complex biology. The models reveal significant limitations in conventional imaging techniques and demonstrate enhanced drug resistance compared to traditional 2D cultures. These findings could reshape how pharmaceutical companies evaluate nanocarrier-based therapies before clinical trials.
In what could represent a significant shift for cancer drug development, new research into three-dimensional tumor modeling is challenging long-standing practices in pharmaceutical testing. According to recent reports, advanced spheroid models of pancreatic ductal adenocarcinoma (PDAC) are revealing critical limitations in conventional imaging methods while providing more accurate predictions of drug resistance.